Pathologic Response to Neoadjuvant Nivolumab Predicts Improved Survival in HPV‑Negative Head and Neck Cancer
Highlight
– In a pooled cohort (n=79) from two neoadjuvant nivolumab trials, a pathologic treatment effect (pTE) threshold of 57% defined responders versus low/nonresponders.
– Among 40 patients with HPV‑negative resectable HNSCC, pathologic responders (pTE >57%) had 100% 3‑year disease‑free and overall survival versus 66.8% and 73.3%, respectively, in low/nonresponders.
– In HPV‑positive disease, high 3‑year disease‑free survival was observed regardless of pTE, underscoring different prognostic baselines and implications for biomarker use by HPV status.
Background: clinical context and unmet need
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.